These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 23693095

  • 1. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.
    Márk Á, Hajdu M, Váradi Z, Sticz TB, Nagy N, Csomor J, Berczi L, Varga V, Csóka M, Kopper L, Sebestyén A.
    BMC Cancer; 2013 May 22; 13():250. PubMed ID: 23693095
    [Abstract] [Full Text] [Related]

  • 2. [Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas].
    Márk Á.
    Magy Onkol; 2014 Jun 22; 58(2):143-8. PubMed ID: 25010764
    [Abstract] [Full Text] [Related]

  • 3. Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.
    Nagy N, Hajdu M, Márk Á, Király PA, Tóth M, Dankó T, Csóka M, Sebestyén A.
    Tumour Biol; 2016 Oct 22; 37(10):13695-13704. PubMed ID: 27473087
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A, Zang C, Chumduri C, Dörken B, Daniel PT, Scholz CW.
    Int J Cancer; 2013 Oct 15; 133(8):1813-24. PubMed ID: 23580240
    [Abstract] [Full Text] [Related]

  • 11. Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.
    Quesada AE, Nguyen ND, Rios A, Brown RE.
    Int J Clin Exp Pathol; 2014 Oct 15; 7(12):8732-9. PubMed ID: 25674239
    [Abstract] [Full Text] [Related]

  • 12. Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach.
    Chaturvedi NK, Rajule RN, Shukla A, Radhakrishnan P, Todd GL, Natarajan A, Vose JM, Joshi SS.
    Mol Cancer Ther; 2013 Oct 15; 12(10):2006-17. PubMed ID: 23963361
    [Abstract] [Full Text] [Related]

  • 13. mTOR activity in AIDS-related diffuse large B-cell lymphoma.
    Browne SH, Diaz-Perez JA, Preziosi M, King CC, Jones GA, Jain S, Sun X, Reid EG, VandenBerg S, Wang HY.
    PLoS One; 2017 Oct 15; 12(2):e0170771. PubMed ID: 28192480
    [Abstract] [Full Text] [Related]

  • 14. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.
    Witzig TE, Reeder C, Han JJ, LaPlant B, Stenson M, Tun HW, Macon W, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic S, Nowakowski GS, Gupta M.
    Blood; 2015 Jul 16; 126(3):328-35. PubMed ID: 25921059
    [Abstract] [Full Text] [Related]

  • 15. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
    Petrich AM, Leshchenko V, Kuo PY, Xia B, Thirukonda VK, Ulahannan N, Gordon S, Fazzari MJ, Ye BH, Sparano JA, Parekh S.
    Clin Cancer Res; 2012 May 01; 18(9):2534-44. PubMed ID: 22338016
    [Abstract] [Full Text] [Related]

  • 16. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
    Zeng Q, Qin S, Zhang H, Liu B, Qin J, Wang X, Zhang R, Liu C, Dong X, Zhang S, Huang S, Chen L.
    J Cell Physiol; 2018 Jan 01; 233(1):516-529. PubMed ID: 28300280
    [Abstract] [Full Text] [Related]

  • 17. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA, Maeng K, Nawab A, Kaye FJ, Hochwald SN, Zajac-Kaye M.
    J Natl Cancer Inst; 2015 Aug 01; 107(8):. PubMed ID: 25971297
    [Abstract] [Full Text] [Related]

  • 18. Rapamycin can restore the negative regulatory function of transforming growth factor beta 1 in high grade lymphomas.
    Sebestyén A, Márk Á, Hajdu M, Nagy N, Molnár A, Végső G, Barna G, Kopper L.
    Cytokine; 2015 Jun 01; 73(2):219-24. PubMed ID: 25794661
    [Abstract] [Full Text] [Related]

  • 19. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, Yeo W.
    Biochem Pharmacol; 2012 May 01; 83(9):1146-58. PubMed ID: 22285225
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.